Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease

Advances in Experimental Medicine and Biology

Volumn 458, Issue , 1999, Pages 129-134

  Chulay, J ^a   Biron, K ^a   Wang, L ^a   Underwood, M ^a   Chamberlain, S ^a   Frick, L ^a   Good, S ^a   Davis, M ^a   Harvey, R ^a   Townsend, L ^a   Drach, J ^a   Koszalka, G ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 BROMO 5,6 DICHLORO BETA DEXTRO RIBOFURANOSYL BENZIMIDAZOLE; 2 CHLORO 5,6 DICHLORO BETA DEXTRO RIBOFURANOSYL BENZIMIDAZOLE; BENZIMIDAVIR; BENZIMIDAZOLE DERIVATIVE; CIDOFOVIR; FOSCARNET; GANCICLOVIR; RIBONUCLEOSIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; RETINITIS; TASTE DISORDER;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS;

EID: 0033281797     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4743-3_12     Document Type: Conference Paper

References (15)

1. Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome
2. Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(beta-D-ribofuranosyl)benzimidazoles
3. The transcriptional elongation inhibitor 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole inhibits transcription factor IIH-associated protein kinase
4. Inhibition of HCMV DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product
5. Characterization of a temperature-sensitive mutant of the UL15 open reading frame of herpes simplex virus
6. Resistance of HCMV to benzimidazole ribonucleosides results from mutations in both UL89 and UL56
7. Benzimidazoles for the treatment of human cytomegalovirus
8. Antiviral activity and mechanism of action of 1263W94, a benzimidazole riboside inhibitor of human cytomegalovirus
9. Activity against Epstein-Barr virus of benzimidazole riboside 1263W94 (5,6-dichloro-2(isopropylamino)-1-b-L-ribofuranosyl-1-H-benzimidazole)
10. Pharmacokinetics and metabolism in rats and monkeys of 1263W94, a potent and selective inhibitor of human cytomegalovirus
11. A phase I trial evaluating the tolerability and pharmacokinetics of 1263W94 following single oral administration of escalating doses in normal healthy volunteers
12. A phase I tolerability and pharmacokinetics trial of 1263W94, a novel anti-HCMV agent, in HIV-infected volunteers
13. Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis
14. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant
15. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes